source
- Regeneron's Pasatru receives FDA approval for ultra-rare bone-growth disease FOPRegeneron Pharmaceuticals has secured FDA approval for Pasatru, a therapy aimed at treating fibrodysplasia ossificans progressiva (FOP), an ultra‑rare condition in which bone forms in soft tissues.…
- Merck and Moderna report personalized mRNA vaccine delays melanoma recurrence in late-stage trialMerck and Moderna announced that a personalized mRNA cancer vaccine, when combined with standard therapy, slowed the return of melanoma and reduced its spread in a late-stage clinical study. The tr…